LMR Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History

LMR Partners’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-5,800	Closed	-$1.57M	–	1362
2025 Q1	$1.57M	Buy	+5,800	New	+$1.49M	0.01%	702
2024 Q3	–	Sell	-109,900	Closed	-$26.7M	–	1261
2024 Q2	$26.7M	Buy	109,900 +59,300	+117%	+$9.36M	0.23%	92
2024 Q1	$7.56M	Sell	50,600 -6,100	-11%	-$1.02M	0.08%	231
2023 Q4	$10.9M	Hold	56,700	–	–	0.12%	190
2023 Q3	$10M	Sell	56,700 -35,200	-38%	-$6.72M	0.11%	188
2023 Q2	$17.5M	Buy	+91,900	New	+$18.2M	0.19%	119

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

LMR Partners's ALNY Position: Q2 2026 in Review

LMR Partners increased its Alnylam Pharmaceuticals (ALNY) stake by 80% in Q2 2026, buying an estimated $18M and bringing the position to 134,214 shares worth $40.4M. The position accounts for 0.15% of the portfolio, ranked #145.

LMR Partners first reported a position in ALNY in Q1 2015 and has held it in 19 quarters since. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

LMR Partners held 134,214 shares of Alnylam Pharmaceuticals worth $40.4M as of Q2 2026.
LMR Partners bought 59,553 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $18M.
Alnylam Pharmaceuticals made up 0.15% of LMR Partners's portfolio in Q2 2026, its #145 holding.
LMR Partners first reported a position in Alnylam Pharmaceuticals in Q1 2015 and has held it in 19 quarters since.
790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on LMR Partners's 13F filing for Q2 2026, filed 14 Aug 2026.